Amneal Reports 8% Revenue Growth in 2025, Guides for Continued Expansion in 2026
Event summary
- Amneal reported $3.02 billion in full-year 2025 revenue, up 8% from 2024, with Q4 revenue at $814 million, an 11% increase year-over-year.
- Specialty segment revenue grew 19% in 2025, driven by CREXONT® and UNITHROID®, while Affordable Medicines segment revenue increased 4%.
- Adjusted EBITDA for 2025 was $688 million, a 10% increase from 2024, with adjusted diluted EPS at $0.83 for the year.
- Amneal guided for 2026 revenue of $3.05 billion to $3.15 billion, with adjusted EBITDA expected between $720 million and $760 million.
- The company launched BREKIYA® autoinjector and secured approvals for two inhalation products and two biosimilars in 2025.
The big picture
Amneal's 2025 performance highlights its ability to execute a diversified growth strategy, with strong contributions from both its Specialty and Affordable Medicines segments. The company's focus on innovation, as evidenced by new product launches and approvals, positions it well in a competitive healthcare landscape. The 2026 guidance suggests continued confidence in its operational and financial strategy, despite potential headwinds in the pharmaceutical industry.
What we're watching
- Revenue Diversification
- How Amneal's strategy of diversifying its portfolio across Specialty, Affordable Medicines, and AvKARE segments will impact its long-term growth and resilience.
- Product Innovation
- Whether the successful launches of CREXONT®, UNITHROID®, and BREKIYA® can sustain the company's growth momentum in the competitive pharmaceutical market.
- Financial Discipline
- The pace at which Amneal can maintain its adjusted EBITDA margin expansion while investing in new product development and commercial investments.
Related topics